Deconstructing Racial Differences in Receipt of Secondary Stroke Prevention Agents in Nursing Homes

2007 ◽  
Vol 13 (2) ◽  
pp. 53-66
Author(s):  
Kate Lapane
Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
Karen Albright ◽  
Amelia K Boehme ◽  
Virginia Howard ◽  
George Howard ◽  
Suzanne Judd ◽  
...  

Background and Purpose: Secondary stroke prevention medications (SSPs) have been shown to prevent recurrent stroke, but few national reports of prescribing SSPs are available from hospitals regardless of their participation in national quality improvement programs. We examined SSP prescribing at discharge following hospitalization for adjudicated incident ischemic stroke (IS) in a large national cohort and unselected hospitals. Methods: We performed a retrospective review of incident IS admissions within the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort; admissions were to unselected hospitals. Exclusions were history of stroke, hospital death, missing data, and prevalent use of the medication of interest. Race, sex, age, rurality of residence (as defined by Rural Urban Commuting Area codes) were obtained at REGARDS baseline. Admission and discharge medications were obtained from hospital records. Associations between characteristics and discharge SSP prescriptions were examined using logistic regression adjusting for race, age, sex, and rurality. Results: From 2003-2011, of 657 IS, 429 met inclusion criteria. Mean age of participants was 73 (42% Black, 49% female, 27% non-urban). Antithrombotic therapy (antiplatelet/anticoagulant) was prescribed for 87%, statins 36% (10% 80mg), and ACE-I/ARB for 16%. We observed no statistically significant differences in prescribing antithrombotics or statins by race, sex, age, or rurality. Participants in non-urban areas had lower odds of ACE-I/ARB at discharge (OR 0.38, 0.15-0.98), with no differences by race, sex, or age. Conclusions: The majority of participants with incident IS within REGARDS were newly prescribed antithrombotics at discharge but alarmingly few were newly prescribed statins or ACE-I/ARBs. Our findings among incident SSP users differ from previous reports among prevalent users within hospitals participating in a national quality improvement program. More studies of quality of care after IS at unselected hospitals are needed.


2021 ◽  
Vol 24 ◽  
pp. S74
Author(s):  
J. Jiang ◽  
D. Li ◽  
J. Horrow ◽  
H. Tamada ◽  
A. Kahl ◽  
...  

2011 ◽  
Vol 43 (4) ◽  
pp. 199-204 ◽  
Author(s):  
Michelle M. Menard ◽  
Don B. Smith ◽  
Cristina Taormina

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Katarina D. Kovacevic ◽  
Stefan Greisenegger ◽  
Agnes Langer ◽  
Georg Gelbenegger ◽  
Nina Buchtele ◽  
...  

AbstractThe effect of conventional anti-platelet agents is limited in secondary stroke prevention, and their effects are blunted under high shear stress in the presence of increased levels of circulating von Willebrand factor (VWF). VWF is critically involved in thrombus formation at sites of stenotic extracranial/intracranial arteries. A third generation anti-VWF aptamer (BT200) has been generated which could be useful for secondary stroke prevention. To characterize the effects of BT200 in blood of patients with large artery atherosclerosis stroke (LAA). Blood samples were obtained from 33 patients with acute stroke or transient ischemic attack to measure inhibition of VWF activity and VWF-dependent platelet function. Patients who received clopidogrel or dual antiplatelet therapy did not differ in VWF dependent platelet function tests from aspirin treated patients. Of 18 patients receiving clopidogrel with or without aspirin, only 3 had a prolonged collagen adenosine diphosphate closure time, and none of the patients had ristocetin induced aggregation in the target range. BT200 concentration-dependently reduced median VWF activity from 178 to < 3%, ristocetin induced platelet aggregation from 40U to < 10U and prolonged collagen adenosine diphosphate closure times from 93 s to > 300 s. Baseline VWF activity correlated (r = 0.86, p < 0.001) with concentrations needed to reduce VWF activity to < 20% of normal, indicating that BT200 acts in a target concentration-dependent manner. Together with a long half-life supporting once weekly administration, the safety and tolerability observed in an ongoing phase I trial, and the existence of a reversal agent, BT200 is an interesting drug candidate.


Sign in / Sign up

Export Citation Format

Share Document